Was Jim Cramer Right About Builders FirstSource, Inc. (BLDR)?
We recently published a list of In this article, we are going to take a look at where Builders FirstSource, Inc. (NYSE:BLDR) stands against other stocks that Jim Cramer discusses.
In an older call, a viewer asked about buying the dip in Builders FirstSource, Inc. (NYSE:BLDR), especially after the stock approached a key technical level. Cramer expressed concern about broader housing sector weakness, citing negative commentary from Home Depot and Lowe's at the time. He replied:
'You know how much I like this company but I've got to tell you both commentary from Home Depot and Lowe's was not instructive… not constructive… and it makes me concerned that there is still another leg to fall here. Let's do this… 162… if it goes to 150, then let's do something, but we've got to wait.'
Craner's call to wait proved smart, as the stock fell -27.56%.
Builders FirstSource Inc. (NYSE:BLDR) is a leading supplier and manufacturer of building materials, trusses, and prefabricated components to professional contractors in the residential construction industry.
On May 20, Cramer admitted he's intrigued by the stock and gave his own analysis on it:
'Hey, by the way, while we're talking about building materials, can we not forget about Builders FirstSource, which is a major consolidator in what used to be a highly fragmented industry? This stock's been a huge long-term performer, but it's peaked early last year, and the stock has been tumbling ever since because it's tied not too directly to a not-so-hot housing market, and that's because of interest rates. Unlike the rest of the market, Builders FirstSource didn't recover much in April. Then, when the company reported on May 1st, the stock went lower still because management lowered their full-year forecast.
A crane lifting a truss during the construction of a new building.
Now I always tell you that executives sell their stock for all sorts of reasons… but they only buy their own stock in the open market for one reason: because they think it's going to go higher. So that's certainly an encouraging thing to see from Mr. Levy at Builders FirstSource. Consider me intrigued.'
Overall, BLDR ranks 6th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of BLDR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
23 minutes ago
- Yahoo
Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT
Keith Weiss from Morgan Stanley maintained a Hold rating on Snowflake Inc. (NYSE:SNOW) on June 4, keeping the associated price target at $200.00. The analyst has an optimistic yet cautious outlook on the company. Weiss noted that its recent Investor Day showcased several key product innovations, particularly in AI integration across the company's offerings, which provides Snowflake Inc. (NYSE:SNOW) a strong foundation for future growth. A software engineer at work, surrounded by a wall of computer monitors connected to a 'Data Cloud' platform. However, the analyst also reasoned that the event failed to provide substantial financial updates, which led to uncertainty surrounding Snowflake Inc.'s (NYSE:SNOW) immediate financial trajectory. Weiss acknowledged that the company is continuously expanding its capabilities to handle unstructured, structured, and multi-modal data. Despite that, he opined that the stock may be priced high compared to its near-term growth prospects, which can be corroborated by its current valuation at 55 times the projected free cash flow for 2026. While Snowflake Inc. (NYSE:SNOW) has attractive long-term potential, Weiss justified the Hold rating by recommending that investors wait for a more favorable entry point before raising their investments. Snowflake Inc. (NYSE:SNOW) provides cloud data warehousing software. Its offerings include Data Cloud, and its platform supports a number of use cases, including data engineering, data warehousing, data sharing, data science, data application development, and more. While we acknowledge the potential of SNOW as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
